Celldex Therapeutics, Inc. (CLDX)

NCM – Real Time Price. Currency in USD

32.00

-0.28 (-0.87%)

At close: May 12, 2026, 4:00 PM EDT

32.00

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

07.05.2026

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago.

07.05.2026

Celldex Reports First Quarter Financial Results and Provides Corporate Update

HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

07.05.2026

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M raised in April 2026) supports operations through 2027, mitigating near-term dilution risk. Phase 3 enrollment for CSU completed six months early; top-line data expected Q4/26, with BLA filing planned for 2027.

04.05.2026

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

13.04.2026

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET.

06.04.2026

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $345 million, excluding underwriting discounts and commissions and other offering-related expenses.

02.04.2026

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has also granted the underwriters a 30-day option to purchase up to an additional 1,551,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters' option, if any, of approximately $300 million, excluding the underwriting discounts and commissions and other offering-related expenses. The offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Celldex Reports First Quarter Financial Results and Provides Corporate Update

HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

06.04.2026

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

02.04.2026

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

01.04.2026

Celldex Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Celldex Therapeutics, Inc. (CLDX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Videos

No Data

Press releases

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Announces Proposed Public Offering of Common Stock

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Videos

No Data

Press releases

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Announces Proposed Public Offering of Common Stock

Search stocks

Celldex Therapeutics, Inc. (CLDX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Videos

No Data

Press releases

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Announces Proposed Public Offering of Common Stock

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Videos

No Data

Press releases

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Announces Proposed Public Offering of Common Stock